These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 22764744)

  • 1. Pharmacokinetic properties of IB1001, an investigational recombinant factor IX, in patients with haemophilia B: repeat pharmacokinetic evaluation and sialylation analysis.
    Martinowitz U; Shapiro A; Quon DV; Escobar M; Kempton C; Collins PW; Chowdary P; Makris M; Mannucci PM; Morfini M; Valentino LA; Gomperts E; Lee M
    Haemophilia; 2012 Nov; 18(6):881-7. PubMed ID: 22764744
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics, safety and efficacy of a recombinant factor IX product, trenonacog alfa in previously treated haemophilia B patients.
    Collins PW; Quon DVK; Makris M; Chowdary P; Kempton CL; Apte SJ; Ramanan MV; Hay CRM; Drobic B; Hua Y; Babinchak TJ; Gomperts ED
    Haemophilia; 2018 Jan; 24(1):104-112. PubMed ID: 28833808
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Revised terminal half-life of nonacog alfa as derived from extended sampling data: A real-world study involving 64 haemophilia B patients on nonacog alfa regular prophylaxis.
    Tardy B; Lambert T; Chamouni P; Montmartin A; Trossaert M; Claeyssens S; Berger C; Ardillon L; Gay V; Delavenne X; Harroche A; Chelle P
    Haemophilia; 2022 Jul; 28(4):542-547. PubMed ID: 35420242
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics, Efficacy, and Safety of Nonacog Alfa in Previously Treated Patients with Moderately Severe to Severe Hemophilia B.
    Korth-Bradley JM; Rendo P; Smith L; Altisent C
    Clin Ther; 2016 Apr; 38(4):936-44. PubMed ID: 26969334
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation between FIX genotype and pharmacokinetics of Nonacog alpha according to a multicentre Italian study.
    Morfini M; Dragani A; Paladino E; Radossi P; Di Minno G; Mazzucconi MG; Rossetti G; Barillari G; Napolitano M; Tagariello G
    Haemophilia; 2016 Jul; 22(4):537-42. PubMed ID: 26988465
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A prospective registry of European haemophilia B patients receiving nonacog alfa, recombinant human factor IX, for usual use.
    Berntorp E; Keeling D; Makris M; Tagliaferri A; Male C; Mauser-Bunschoten EP; Musso R; Roca CA; Hassoun A; Kollmer C; Charnigo R; Baumann J; Rendo P
    Haemophilia; 2012 Jul; 18(4):503-9. PubMed ID: 22044794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics, efficacy and safety of BAX326, a novel recombinant factor IX: a prospective, controlled, multicentre phase I/III study in previously treated patients with severe (FIX level <1%) or moderately severe (FIX level ≤2%) haemophilia B.
    Windyga J; Lissitchkov T; Stasyshyn O; Mamonov V; Rusen L; Lamas JL; Oh MS; Chapman M; Fritsch S; Pavlova BG; Wong WY; Abbuehl BE
    Haemophilia; 2014 Jan; 20(1):15-24. PubMed ID: 23834666
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of a novel extended half-life glycoPEGylated factor IX, nonacog beta pegol (N9-GP) in previously treated patients with haemophilia B: results from two phase 3 clinical trials.
    Tiede A; Abdul-Karim F; Carcao M; Persson P; Clausen WHO; Kearney S; Matsushita T; Negrier C; Oldenburg J; Santagostino E; Young G
    Haemophilia; 2017 Jul; 23(4):547-555. PubMed ID: 28233381
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Confirmation of longer FIX activity half-life with prolonged sample collection after single doses of nonacog alfa in patients with haemophilia B.
    Hua B; Wu R; Sun F; Luo B; Alvey C; Labadie R; Qu PR; Korth-Bradley JM; Rendo P
    Thromb Haemost; 2017 Jun; 117(6):1052-1057. PubMed ID: 28331929
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A cross-over pharmacokinetic study of a double viral inactivated factor IX concentrate (15 nm filtration and SD) compared to a SD factor IX concentrate.
    Goudemand J; Peynet J; Chambost H; Négrier C; Briquel ME; Claeyssens S; Derlon-Borel A; Guérois C; Caron C; Scherrmann JM; Debray M; Bridey F
    Thromb Haemost; 1998 Dec; 80(6):919-24. PubMed ID: 9869161
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Once-weekly prophylactic treatment vs. on-demand treatment with nonacog alfa in patients with moderately severe to severe haemophilia B.
    Kavakli K; Smith L; Kuliczkowski K; Korth-Bradley J; You CW; Fuiman J; Zupančić-Šalek S; Abdul Karim F; Rendo P
    Haemophilia; 2016 May; 22(3):381-8. PubMed ID: 26823276
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic study of a high-purity factor IX concentrate (Factor IX Grifols) with a 6-month follow up in previously treated patients with severe haemophilia B.
    Aznar JA; Cabrera N; Matysiak M; Zawilska K; Gercheva L; Antonov A; Montañés M; Páez AM; Lissitchkov T
    Haemophilia; 2009 Nov; 15(6):1243-8. PubMed ID: 19659601
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trenonacog alfa for prophylaxis, on-demand and perioperative management of hemophilia B.
    Brennan Y; Curnow J; Favaloro EJ
    Expert Opin Biol Ther; 2018 Jan; 18(1):95-100. PubMed ID: 29172774
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Head-to-head comparison of the pharmacokinetic profiles of a high-purity factor IX concentrate (AlphaNine®) and a recombinant factor IX (BeneFIX®) in patients with severe haemophilia B.
    Lissitchkov T; Matysiak M; Zavilska K; Laguna P; Gercheva L; Antonov A; Moret A; Caunedo P; Aznar JA; Woodward MK; Páez A
    Haemophilia; 2013 Sep; 19(5):674-8. PubMed ID: 23647607
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multicentre, randomized, open-label study of on-demand treatment with two prophylaxis regimens of recombinant coagulation factor IX in haemophilia B subjects.
    Valentino LA; Rusen L; Elezovic I; Smith LM; Korth-Bradley JM; Rendo P
    Haemophilia; 2014 May; 20(3):398-406. PubMed ID: 24418368
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improvement in health-related quality of life in patients with haemophilia B treated with nonacog beta pegol, a new extended half-life recombinant FIX product.
    Chowdary P; Kearney S; Regnault A; Hoxer CS; Yee DL
    Haemophilia; 2016 Jul; 22(4):e267-74. PubMed ID: 27352908
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical efficacy, safety and pharmacokinetic properties of the plasma-derived factor IX concentrate Haemonine in previously treated patients with severe haemophilia B.
    Serban M; Skotnicki AB; Colovic M; Jinca C; Klukowska A; Laguna P; Wolf DM
    Haemophilia; 2012 Mar; 18(2):175-81. PubMed ID: 21812863
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population pharmacokinetics of recombinant factor IX: implications for dose tailoring.
    Björkman S
    Haemophilia; 2013 Sep; 19(5):753-7. PubMed ID: 23731351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-factor consumption for major surgery in haemophilia B with long-acting recombinant glycoPEGylated factor IX.
    Escobar MA; Tehranchi R; Karim FA; Caliskan U; Chowdary P; Colberg T; Giangrande P; Giermasz A; Mancuso ME; Serban M; Tsay W; Mahlangu JN
    Haemophilia; 2017 Jan; 23(1):67-76. PubMed ID: 27480487
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reformulated BeneFix: efficacy and safety in previously treated patients with moderately severe to severe haemophilia B.
    Lambert T; Recht M; Valentino LA; Powell JS; Udata C; Sullivan ST; Roth DA
    Haemophilia; 2007 May; 13(3):233-43. PubMed ID: 17498071
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.